Difference between revisions of "Gautret P, et al, Int J Antimicrob Agents (2020), cited as Ref 82 in DOI:10.1007/s11886-020-01292-3 (Q10591)"
Jump to navigation
Jump to search
(Created a new Item: #quickstatements; #temporary_batch_1592419510025) |
(Added link to [sliswiki]: Gautret P, et al, Int J Antimicrob Agents (2020), cited as Ref 82 in DOI:10.1007/s11886-020-01292-3, #quickstatements; #temporary_batch_1592946843269) |
||||||||||||||
| (9 intermediate revisions by the same user not shown) | |||||||||||||||
| Property / title | |||||||||||||||
| + | Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial;105949. (English) | ||||||||||||||
| Property / title: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial;105949. (English) / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / First Author string | |||||||||||||||
| + | Gautret P | ||||||||||||||
| Property / First Author string: Gautret P / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Second Author string | |||||||||||||||
| + | Lagier J-C | ||||||||||||||
| Property / Second Author string: Lagier J-C / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Third Author string | |||||||||||||||
| + | Parola P | ||||||||||||||
| Property / Third Author string: Parola P / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Fourth Author string | |||||||||||||||
| + | Hoang VT | ||||||||||||||
| Property / Fourth Author string: Hoang VT / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Fifth Author string | |||||||||||||||
| + | Meddeb L | ||||||||||||||
| Property / Fifth Author string: Meddeb L / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Sixth Author string | |||||||||||||||
| + | Mailhe M | ||||||||||||||
| Property / Sixth Author string: Mailhe M / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Publication Date | |||||||||||||||
| + | 2020
| ||||||||||||||
| Property / Publication Date: 2020 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Published In Name String | |||||||||||||||
| + | Int J Antimicrob Agents | ||||||||||||||
| Property / Published In Name String: Int J Antimicrob Agents / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| links / sliswiki / name | links / sliswiki / name | ||||||||||||||
| + | |||||||||||||||
Latest revision as of 21:15, 23 June 2020
Cited in: "Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response" Research article published in Curr Cardiol Rep; 2020 04 21 ; 22 (5) 32.
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Gautret P, et al, Int J Antimicrob Agents (2020), cited as Ref 82 in DOI:10.1007/s11886-020-01292-3
|
Cited in: "Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response" Research article published in Curr Cardiol Rep; 2020 04 21 ; 22 (5) 32.
|
Statements
Q10356 (Deleted Item)
0 references
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial;105949. (English)
0 references
Gautret P
0 references
Lagier J-C
0 references
Parola P
0 references
Hoang VT
0 references
Meddeb L
0 references
Mailhe M
0 references
2020
0 references
Int J Antimicrob Agents
0 references